Haemonetics (HAE) Cash from Financing Activities (2009 - 2026)

Haemonetics has reported Cash from Financing Activities for 18 years, with the latest figure at -$51.5 million in Q2 2026.

• On a quarterly basis, Cash from Financing Activities fell 2010.07% year-over-year to -$51.5 million in Q2 2026; TTM through Jun 2026 was -$227.5 million, a 0.1% change from a year earlier, with the FY2026 full-year figure at -$178.5 million, down 264.0% from the prior year.
• Cash from Financing Activities was -$51.5 million for Q2 2026 at Haemonetics, up from -$101.5 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $333.7 million in Q2 2024, with the low at -$151.4 million in Q1 2025.
• Average Cash from Financing Activities over 5 years is -$10.2 million, with a median of -$8.8 million recorded in 2022.
• The largest YoY upside for Cash from Financing Activities was 55901.34% in 2024 against a maximum downside of 3861.45% in 2024.
• Over 5 years, Cash from Financing Activities stood at -$49.7 million in 2022, then soared by 320.27% to $109.4 million in 2023, then tumbled by 98.74% to $1.4 million in 2024, then surged by 47.32% to $2.0 million in 2025, then tumbled by 2634.58% to -$51.5 million in 2026.
• The last three Cash from Financing Activities figures came in at -$51.5 million (Q2 2026), -$101.5 million (Q1 2026), and $2.0 million (Q4 2025), per Business Quant data.